Puma Biotechnology (NASDAQ:PBYI) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Puma Biotechnology (NASDAQ:PBYI) in a research note published on Friday, Benzinga reports. The firm currently has a $7.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com cut Puma Biotechnology from a buy rating to a hold rating in a research note on Wednesday, April 10th.

Puma Biotechnology Trading Down 2.0 %

Shares of NASDAQ:PBYI traded down $0.10 during midday trading on Friday, reaching $4.86. 390,616 shares of the company’s stock were exchanged, compared to its average volume of 286,506. The stock has a market cap of $234.30 million, a price-to-earnings ratio of 14.73, a P/E/G ratio of 2.82 and a beta of 1.31. Puma Biotechnology has a fifty-two week low of $2.13 and a fifty-two week high of $7.73. The firm’s 50 day simple moving average is $5.35 and its two-hundred day simple moving average is $4.66. The company has a debt-to-equity ratio of 1.23, a current ratio of 1.57 and a quick ratio of 1.50.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, February 29th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.07). The company had revenue of $72.20 million for the quarter, compared to analysts’ expectations of $73.22 million. Puma Biotechnology had a return on equity of 37.69% and a net margin of 6.79%. As a group, sell-side analysts forecast that Puma Biotechnology will post 0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Crestline Management LP boosted its position in Puma Biotechnology by 6.5% in the 4th quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 2,135 shares during the period. Jump Financial LLC raised its stake in shares of Puma Biotechnology by 26.6% in the third quarter. Jump Financial LLC now owns 24,690 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 5,190 shares in the last quarter. Ritholtz Wealth Management purchased a new position in Puma Biotechnology in the fourth quarter valued at $66,000. Assenagon Asset Management S.A. grew its stake in Puma Biotechnology by 23.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 85,039 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 15,897 shares in the last quarter. Finally, Citigroup Inc. purchased a new stake in Puma Biotechnology during the 3rd quarter worth about $262,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.